

# REVIVING HOPE

With a median OS of 23 months,  
RYBREVANT® offers a second chance for post-platinum  
EGFR E20i-mutated advanced NSCLC\*



 **RYBREVANT**<sup>™</sup>  
(amivantamab) Injection for IV Use  
350 mg/7 mL (50 mg/mL)

**The first and only targeted therapy approved for  
EGFR Exon 20 insertion mutations in advanced NSCLC.**

**Johnson & Johnson**

E20i: Exon 20 insertion; NSCLC: non-small cell lung cancer; OS: overall survival; EGFR: epidermal growth factor receptor.  
Reference: Lopez, P. Garrido et al. J Thor Onc Vol. 18 (4S); 536 DOI: [https://doi.org/10.1016/S1556-0864\(23\)00257-5](https://doi.org/10.1016/S1556-0864(23)00257-5)

Please refer to the local package insert before prescribing. © 2024 Johnson & Johnson. All rights reserved.